ArticleFrontiers in microbiology2026
Molecular epidemiology and antimicrobial resistance profiles of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clostridioides difficile is a leading cause of antibiotic-associated diarrhoea and a growing public health concern, yet data on its genomic characteristics and antimicrobial resistance in Northwest China remain scarce. Methods: This study investigated the molecular epidemiology and resistance profiles of C. difficile in Xi'an using 149 toxigenic isolates recovered from diarrhoeal stool samples collected across seven hospitals between 2018 and 2025. Isolates were characterised by whole-genome sequencing (WGS), multilocus sequence typing (MLST), and PCR-ribotyping, with antimicrobial susceptibility determined by the Etest method. Results: The predominant toxin profile was A+B+CDT- (88.6%, 132/149), followed by A-B+CDT- (8.7%, 13/149) and A+B+CDT+ (2.7%, 4/149); binary toxin (CDT)-positive isolates were exclusively A+B+. MLST and ribotyping resolved 29 sequence types (STs) and 48 ribotypes (RTs), with ST42/RT106 (17.4%), ST3/RT001 (9.4%), and ST54/RT012 (8.7%) the most prevalent. All isolates remained susceptible to metronidazole and vancomycin, whereas high resistance proportions were observed for ciprofloxacin (84.6%), erythromycin (56.4%), and clindamycin (53.7%). The Thr82Ile substitution in GyrA was detected in fluoroquinolone-resistant isolates, and the Arg505Lys substitution in RpoB in rifampicin-resistant isolates. Conclusion: These findings establish, to our knowledge, the first comprehensive genomic profile of C. difficile in Xi'an and may inform regional surveillance and antimicrobial stewardship efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.